Desquamative interstitial pneumonia as the initial manifestation of systemic sclerosis.
Summary of "Desquamative interstitial pneumonia as the initial manifestation of systemic sclerosis."
Interstitial lung disease (ILD) is a frequent pulmonary complication of systemic sclerosis (SSc), and nonspecific interstitial pneumonia is the most commonly recognized pattern of lung injury in these patients. In this report, we describe a never-smoker female presenting with Raynaud phenomenon and ILD that demonstrated desquamative interstitial pneumonia (DIP) on surgical lung biopsy. After 8 months, she was diagnosed with pulmonary hypertension at which time clinical examinations and serologic findings established the diagnosis of SSc. This case report expands the spectrum of patterns of ILD seen in association with SSc to include DIP.
Affiliation
From the *Respiratory Institute, Cleveland Clinic, Cleveland, OH; and daggerOrthopedic & Rheumatologic Institute, Cleveland Clinic, Cleveland, OH.
Journal Details
This article was published in the following journal.
Name: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Pages: 284-6
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20808169
- DOI: http://dx.doi.org/10.1097/RHU.0b013e3181eed86d
Medical and Biotech [MESH] Definitions
Cryptogenic Organizing Pneumonia
An interstitial lung disease of unknown etiology, occurring between 21-80 years of age. It is characterized by a dramatic onset of a "pneumonia-like" illness with cough, fever, malaise, fatigue, and weight loss. Pathological features include prominent interstitial inflammation without collagen fibrosis, diffuse fibroblastic foci, and no microscopic honeycomb change. There is excessive proliferation of granulation tissue within small airways and alveolar ducts.
Mycoplasma Ovipneumoniae
A species of gram-negative bacteria originally isolated from the LUNGS; TRACHEA; and NASAL CAVITY of SHEEP. It causes chronic interstitial pneumonia (PNEUMONIA, MYCOPLASMA) in both SHEEP and GOATS.
Idiopathic Interstitial Pneumonias
A group of interstitial lung diseases with no known etiology. There are several entities with varying patterns of inflammation and fibrosis. They are classified by their distinct clinical-radiological-pathological features and prognosis. They include IDIOPATHIC PULMONARY FIBROSIS; CRYPTOGENIC ORGANIZING PNEUMONIA; and others.
Pneumocystis Infections
Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally.
Pneumonia, Mycoplasma
Interstitial pneumonia caused by extensive infection of the lungs (LUNG) and BRONCHI, particularly the lower lobes of the lungs, by MYCOPLASMA PNEUMONIAE in humans. In SHEEP, it is caused by MYCOPLASMA OVIPNEUMONIAE. In CATTLE, it may be caused by MYCOPLASMA DISPAR.
PubMed Articles
Desquamative interstitial pneumonia.
Tazelaar H D, Wright J L & Churg A (2010) Histopathology Desquamative interstitial pneumonia Desquamative interstitial pneumonia (DIP) is one of the rarest of the idiopathic interstitial pneumonias....
Acute exacerbations of fibrotic interstitial lung disease.
Churg A, Wright J L & Tazelaar H D (2010) Histopathology Acute exacerbations of fibrotic interstitial lung disease An acute exacerbation is the development of acute lung injury, usually resulting in...
Interstitial lung disease in systemic sclerosis.
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies. ILD develops in up...
Smoking and subclinical interstitial lung disease.
The relationships between cigarette smoking and heart disease, lung cancer, and chronic obstructive pulmonary disease (COPD) are well known; in contrast, the topic of the relationship between smoking...
Biomarkers of Scleroderma Lung Disease: Recent Progress.
This article reviews the clinical background and significance of selected biomarkers that have been studied in relation to systemic sclerosis, or scleroderma, a devastating connective tissue disease w...
Clinical Trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious, life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the connective ti...
The aim of this study was to assess serum N-terminal proBNP (NT-proBNP) in systemic sclerosis patients and to establish whether it reflects the severity of RV overload.
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
Although the aetiology of SSc-PAH remains elusive, vascular dysfunction seems to be the initial event and statins through their vasculoprotective effect might be of value in the treatment...
AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
To study the safety and tolerability of a hyperimmune goat serum product (AIMSPRO) in the treatment of systemic sclerosis (SSc) through a period of 26 weeks of study participation. The sec...
Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis
Aim: Determination of frequency and nature of coronary involvement (including epicardial and microvascular) among scleroderma patients referred for right heart catheterization.
